Abstract:
PROBLEM TO BE SOLVED: To provide a new opiate compound binding to an opioid receptor. SOLUTION: The compound is represented by formula (II) [wherein, R 1 is alkyl or aralkyl; R 3 , R 4 , R 5 and R 6 are each independently hydrogen, alkyl, -OH, -NH 2 , -NHR, -N(R) 2 , halogen, -OR, -CF 3 , -CN, -NO 2 or -NHC(O)R; when any of R 3 , R 4 , R 5 and R 6 is N(R) 2 , R groups may form cycloalkyl; Rs are each independently alkyl, aryl or aralkyl; and R 7 is hydrogen or alkyl] and a pharmaceutically acceptable salt thereof. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a compound and method for curing a smoking habit and other diseases. SOLUTION: Compounds represented by formulae (I) to (III) and their pharmaceutically acceptable salts are used as active compounds. COPYRIGHT: (C)2009,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a compound to be used for a therapeutic agent for heroin poisoning, an analgesic, easing agent of μ-induced respiratory disorder, cytostatic agent, antimigraine agent, immunity regulator, immunosuppressant, anti-arthritis agent, anti-allergic agent, antiviral agent, antidiarrhea agent, antidepressant, urolith agent, anti-cough agent, therapeutic agent for alcohol poisoning, hypotensive agent or therapeutic agent for obesity by combining with an opioid receptor. SOLUTION: The compound represented by general formula (III), its pharmaceutically acceptable salt, and an opioid receptor binder containing the compound are provided. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a new opiate compound binding to an opioid receptor. SOLUTION: The compound is represented by formula (IV) [wherein, R a and R b are each independently hydrogen or alkyl or R a and R b together form cycloalkyl; Xs are each independently alkyl; O is 5-membered or 6-membered-ring aryl or heteroaryl; Zs are each independently alkyl, -OH, -OR, halogen, -CF 3 , -CN, -NH 2 , -NHR or -N(R) 2 ; when Z is -N(R) 2 , R groups form cycloalkyl; Rs are each independently alkyl, aryl or aralkyl; Ws are each alkyl; n is 0 or an integer of 1-4; y is 0 or an integer of 1-5; z is 0 or an integer of 1-8; and R 5 is alkyl, alkenyl or aralkyl] and a pharmaceutically acceptable salt thereof. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a compound binding with high affinity to kappa opioid receptors. SOLUTION: The invention relates to kappa opioid receptor antagonists that yield significant improvement in functional binding assays to kappa opioid receptors relative to nor-BNI, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide compounds that bind with high affinity to kappa opioid receptors.SOLUTION: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of the antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
Abstract:
PROBLEM TO BE SOLVED: To solve the problem that the necessity of an anti-progestin compound exhibiting higher specificity is left. SOLUTION: A cyclic amine-substituted compound such as N-piperidinyl, especially useful when the 4-position of a 11β-aryl portion is substituted, is provided, because we have found that it has the reduced possibility of toxicity, not only holds the total molecular characteristics of dimethylamino analogues, but also exhibits to strongly bind to progestin receptors, and has a latent progesterone or anti-progesterone activity. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a microelectromechanical system (MEMS) valve device having advantages of quick operation, large valve force and large displacement while consuming minimal power. SOLUTION: The MEMS valve device includes a substrate 20 having an aperture 70 formed therein, a substrate electrode 40, and a movable membrane 60 located on the aperture 70 and having an electrode element layer 62 and biasing element layers 64, 66. At least one resiliently compressible dielectric layer 50 is provided to ensure electrical isolation between the substrate electrode 40 and the electrode element layer 62 of the movable membrane 60. In operation, voltage difference is established between the substrate electrode 40 and the electrode element layer 62 of the movable membrane 60 to move the movable membrane 60 relative to the aperture 70 to thereby controllably adjust the portion of the aperture 70 covered with the movable membrane 60. COPYRIGHT: (C)2008,JPO&INPIT